References
- National Institute for Health and Clinical Excellence. (2008) [online]. Available from: www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed 23 July 2010.
- Onofrio BM, Yaksh TL, Arnold PG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc 1981;56:516–20.
- Belverud S, Mogilner A, Schulder M. Intrathecal pumps. Neurotherapeutics 2008;5(1):114–22.
- Deer T, Winkelmüller W, Erdine S, Bedder M, Burchiel K. Intrathecal therapy for cancer and nonmalignant pain: patient selection and patient management. Neuromodulation 1999;2:55–66.
- Mueller-Schwefe G, Hassenbusch SJ, Reig E. Cost effectiveness of intrathecal therapy for pain. Neuromodulation 1999;2(2):77–87.
- Raphael JH, Gnanadurai TV, Southall JL, Mutagi H, Kapur S. Placebo-controlled single blind study of short-term efficacy of spinal morphine in chronic non-malignant pain. Reg Anesth Pain Med 2006;31(5):47.
- Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. JAMA 1989;262(20):2879–86.
- Kumar K, Kelly M, Pirlot T. Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy. Surg Neurol 2001;55(2):79–88.
- Kumar K, Hunter G, Demeria DD. Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysis. J Neurosurg 2002;97(4):803–10.
- Paice JA, Winkelmüller W, Burchiel K, Racz GB, Prager JP. Clinical realities and economic considerations: efficacy of intrathecal pain therapy. J Pain Symptom Manage 1997;14(3 Suppl):S14–S26.
- de Lissovoy G, Brown RE, Halpern M, Hassenbusch SJ, Ross E. Cost-effectiveness of long-term intrathecal morphine therapy for pain associated with failed back surgery syndrome. Clin Ther 1997;19:96–112.
- Hassenbusch SJ, Paice JA, Patt RB, Bedder MD, Bell GK. Clinical realities and economic considerations: economics of intrathecal therapy. J Pain Symptom Manage 1997;14:S36–S48.
- Joint Formulary Committee. British National Formulary. 57th editionLondon: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2009.
- The Euroqol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990;16(3):199–209.
- Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197–200.
- Simpson BJ, Middleton P, Maddern G. Implantable spinal infusion devices for chronic pain and spasticity: an accelerated systematic review. ASERNIP-S Report No. 42. Adelaide, South Australia: ASERNIP-S, 2003.
- Phillips C. 2009 [online]. Available from: www.whatisseries.co.uk/whatis/pdfs/What_is_a_QALY.pdf. Accessed 30 July 2010.
- Winkelmüller M, Winkelmüller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg 1996;85(3):458–67.
- Raphael JH, Southall JL, Gnanadurai TV, Treharne GJ, Kitas GD. Long-term experience with implanted intrathecal drug administration systems for failed back syndrome and chronic mechanical low back pain. BMC Musculoskel Dis 2002;3:17.
- Paice JA, Penn RD, Shott S. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage 1996;11(2):71–80.
- Anderson VC, Burchiel KJ. A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery 1999;44(2):289–300.
- Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008;336(7651):999–1003.
- Patel VB, Manchikanti L, Singh V, Schultz DM, Hayek SM, Smith HS. Systematic review of intrathecal infusion systems for long-term management of chronic non-cancer pain. Pain Physician 2009;12(2):345–360.